- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05556135
Role Of Serum Adiponectin In The Ealy Detection Of Renal Impairment In Patients With Non Alcoholic Fatty Liver Disease
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Nonalcoholic fatty liver disease (NAFLD) includes different types of liver damage, ranging from simple steatosis and nonalcoholic steatohepatitis (NASH) to liver cirrhosis and even hepatocellular carcinoma.(1) NAFLD is diagnosed by the presence of more than 5% fat accumulation in liver cells after excluding excessive alcohol intake in patients as well as other secondary causes of liver disease, such as drug-induced liver injury, viral and autoimmune hepatitis.(2) The diagnostic criteria for chronic kidney disease (CKD) are either the reduced estimated glomerular filtration rate (eGFR) (<60 mL/min/1.732) and/or abnormal albuminuria and/or overt proteinuria in patients for at least 3 months.(3) The association between NAFLD and CKD has recently attracted the attention of many experts. NAFLD and CKD share some common pathophysiological mechanisms as well as some metabolic risk factors for cardiovascular disease. Some studies have confirmed that the presence of NAFLD increases the risk of CKD and that the degree of liver fibrosis is related to CKD stage,(4) It is crucial to detect early renal impairment in patients with NAFLD to prevent CKD progression, minimize complications, and improve survival (1) Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.(4) Adiponectin is one of the key regulators involved in glucose and lipid metabolism. Further analyses have shown its anti-inflammatory and anti-apoptotic roles in human cells.
Data from large cross sectional studies showed a positive correlation between serum Adiponectin and mortality in chronic kidney disease.(5)
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Mustafa Abdelrafie, master
- Telefonnummer: 01010303737
- E-post: mustafabadary@yahoo.com
Studer Kontakt Backup
- Navn: mohamed elyamany, MD
- Telefonnummer: 01002228914
- E-post: elyamany50@yahoo.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
All patients who fulfil inclusion and exclusion criteria then directed to nephrology unit to do other full investigations ,will be included in this study .
1)Full history and clinical examination .2) Investigation :
All patients will be investigated for detection of renal impairment by :
1)microalbuminurea.
- 2)Urine analyses.
- 3)Kidney function tests.
- 4)calculate GFR.
- 5)Complete blood count .
And also to detect the degree of liver affection by:
- 1)liver function tests .
- 2)abdominal ultrasound to grade fatty liver & determine echogenicity of kidney .
3)Non-invasive blood test to detect degree of hepatic steatosis ( FIB-4 , APRI, fibrosis score ).
4)fibroscane .
- Detection of serum Adiponectin by ELISA technique using (EIA-3418) KIT, DRG international inc., USA *Investigations to control risk factors of Non-alcoholic fatty liver disease: -Calculate Body Mass Index (BMI). - Measuring the fasting blood sugar and HbA1C level in all subjects. -Lipid Profile.
Beskrivelse
Inclusion Criteria:
- Patients with fatty liver aged from 18 to 60 yrs either diabetic or not .
- Patient with normal echogenic kidney in ultrasound and eGFR more than 60 mL/min/1.73m2.
- The Control group are completely healthy subjects without any systemic or liver and kidney affection
Exclusion Criteria:
- 1)Patients less than 18 yrs & more than 60 yrs 2)All patients having any other causes of renal and hepatic disease rather than Diabetes and having any other systemic problem.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
group1
NAFLD patients
|
estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
|
group 2
non NAFLD patients
|
estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Correlate serum Adiponectin level with renal impairment in non-alcoholic fatty liver disease.
Tidsramme: baseline
|
Correlate serum Adiponectin level with renal impairment in non-alcoholic fatty liver disease.
/
|
baseline
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: mohamed hassan, MD, master
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Montesano R, Orci L, Vassalli P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol. 1983 Nov;97(5 Pt 1):1648-52. doi: 10.1083/jcb.97.5.1648.
- Stefan N, Stumvoll M. Adiponectin--its role in metabolism and beyond. Horm Metab Res. 2002 Sep;34(9):469-74. doi: 10.1055/s-2002-34785.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Serum Adiponectin in NAFLD
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nedsatt nyrefunksjon
-
Universitaire Ziekenhuizen KU LeuvenFullførtForekomst av utvidet renal clearance | Risikofaktorer for økt renal clearanceBelgia
-
Andrew B AdamsBristol-Myers SquibbFullført
-
University Health Network, TorontoFullførtGlomerulær filtreringshastighet | Renal blodstrømCanada
-
Oregon Health and Science UniversityFullført
-
Erling Bjerregaard PedersenUniversity of AarhusUkjentRenal rørtransportDanmark
-
Amai Charitable TrustUkjent
-
The Methodist Hospital Research InstituteUkjentAkutt (cellulær) renal allograft avvisningForente stater
-
Universitaire Ziekenhuizen KU LeuvenUkjent
-
Medical University of ViennaFullførtAcidose, Renal Tubular
-
Johns Hopkins UniversityFullførtKlinisk T1 nyremasseForente stater